dihydroxyphenylalanine and Hyperinsulinism studies

Dihydroxyphenylalanine: A beta-hydroxylated derivative of phenylalanine. The D-form of dihydroxyphenylalanine has less physiologic activity than the L-form and is commonly used experimentally to determine whether the pharmacological effects of LEVODOPA are stereospecific.
dopa : A hydroxyphenylalanine carrying hydroxy substituents at positions 3 and 4 of the benzene ring.

Hyperinsulinism: A syndrome with excessively high INSULIN levels in the BLOOD. It may cause HYPOGLYCEMIA. Etiology of hyperinsulinism varies, including hypersecretion of a beta cell tumor (INSULINOMA); autoantibodies against insulin (INSULIN ANTIBODIES); defective insulin receptor (INSULIN RESISTANCE); or overuse of exogenous insulin or HYPOGLYCEMIC AGENTS.

Research Excerpts

Excerpt	Relevance	Reference
"In recent years, 6-l-18F-fluorodihydroxyphenylalanine (18F-DOPA) PET has emerged as a new diagnostic tool for the imaging of neuroendocrine tumors."	8.84	6-L-18F-fluorodihydroxyphenylalanine PET in neuroendocrine tumors: basic aspects and emerging clinical applications. ( Brouwers, AH; Chirakal, R; Gulenchyn, KY; Jager, PL; Koopmans, KP; Marriott, CJ, 2008)
"(18)F-fluorodihydroxyphenylalanine (FDOPA) PET seems to be of limited value to localize pancreatic insulin-secreting tumors in adult with hyperinsulinemic hypoglycemia."	7.81	Dynamic 18F-FDOPA PET Findings After Carbidopa Premedication in 2 Adult Patients With Insulinoma-Related Hyperinsulinemic Hypoglycemia. ( Bachellier, P; Bahougne, T; Goichot, B; Imperiale, A; Namer, IJ; Taïeb, D, 2015)
"In recent years, 6-l-18F-fluorodihydroxyphenylalanine (18F-DOPA) PET has emerged as a new diagnostic tool for the imaging of neuroendocrine tumors."	4.84	6-L-18F-fluorodihydroxyphenylalanine PET in neuroendocrine tumors: basic aspects and emerging clinical applications. ( Brouwers, AH; Chirakal, R; Gulenchyn, KY; Jager, PL; Koopmans, KP; Marriott, CJ, 2008)
"(18)F-fluorodihydroxyphenylalanine (FDOPA) PET seems to be of limited value to localize pancreatic insulin-secreting tumors in adult with hyperinsulinemic hypoglycemia."	3.81	Dynamic 18F-FDOPA PET Findings After Carbidopa Premedication in 2 Adult Patients With Insulinoma-Related Hyperinsulinemic Hypoglycemia. ( Bachellier, P; Bahougne, T; Goichot, B; Imperiale, A; Namer, IJ; Taïeb, D, 2015)
"Weight loss is associated with down-regulation of sympathetic nervous activity but no overall alteration in disposition indices."	1.40	The effects of dietary weight loss on indices of norepinephrine turnover: modulatory influence of hyperinsulinemia. ( Dawood, T; Dixon, JB; Eikelis, N; Esler, MD; Grima, MT; Lambert, EA; Lambert, GW; Masuo, K; Nestel, PJ; Paul, E; Richards, K; Sari, CI; Schlaich, MP; Straznicky, NE, 2014)

Research

Studies (13)

Authors

Clinical Trials (4)

Trial Overview

Trial Outcomes

Safety of F-DOPA PET

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	8 (61.54)	29.6817
2010's	5 (38.46)	24.3611
2020's	0 (0.00)	2.80

Authors	Studies
Straznicky, NE	1
Lambert, EA	1
Grima, MT	1
Eikelis, N	1
Richards, K	1
Nestel, PJ	1
Dawood, T	1
Masuo, K	1
Sari, CI	1
Dixon, JB	1
Esler, MD	1
Paul, E	1
Schlaich, MP	1
Lambert, GW	1
Imperiale, A	2
Sebag, F	2
Vix, M	1
Castinetti, F	1
Kessler, L	1
Moreau, F	1
Bachellier, P	2
Guillet, B	1
Namer, IJ	2
Mundler, O	2
Taïeb, D	3
Bahougne, T	1
Goichot, B	1
Kork, F	1
Blankenstein, O	2
Mohnike, W	1
Höhne, C	1
Minn, H	1
Kauhanen, S	1
Seppänen, M	1
Nuutila, P	1
Tessonnier, L	1
Ghander, C	1
De Micco, C	1
Reynaud, R	1
Palazzo, FF	1
Conte-Devolx, B	1
Henry, JF	1
de Heide, LJ	1
Glaudemans, AW	1
Oomen, PH	1
Apers, JA	1
Totté, ER	1
van Beek, AP	1
de Lonlay, P	1
Simon-Carre, A	1
Ribeiro, MJ	2
Boddaert, N	2
Giurgea, I	1
Laborde, K	1
Bellanné-Chantelot, C	2
Verkarre, V	2
Polak, M	1
Rahier, J	1
Syrota, A	1
Seidenwurm, D	1
Nihoul-Fékété, C	2
Robert, JJ	1
Brunelle, F	2
Jaubert, F	2
Hardy, OT	2
Litman, RS	1
Hernandez-Pampaloni, M	1
Saffer, JR	1
Scheuermann, JS	1
Ernst, LM	1
Freifelder, R	1
Zhuang, H	1
MacMullen, C	1
Becker, S	1
Adzick, NS	1
Divgi, C	1
Alavi, A	1
Stanley, CA	1
Delzescaux, T	1
Valayannopoulos, V	1
Lonlay, P	1
Kapoor, RR	1
Gilbert, C	1
Mohnike, K	1
Fuechtner, F	1
Hussain, K	1
Jager, PL	1
Chirakal, R	1
Marriott, CJ	1
Brouwers, AH	1
Koopmans, KP	1
Gulenchyn, KY	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Effects of SGLT-2 Inhibition on Sympathetic Nervous System Activity in Humans[NCT03912909]	Phase 4	30 participants (Anticipated)	Interventional	2018-08-01	Recruiting
Localization of Focal Forms of Hyperinsulinism of Infancy With 18F-labeled L-fluoro-DOPA PET Scan[NCT00674440]	Phase 2	106 participants (Actual)	Interventional	2004-12-31	Completed
A Phase II Safety and Efficacy Study of 18F-L-Fluoro-DOPA PET/CT Scan Localization of Focal Pancreatic Lesions in Children With Hyperinsulinemic Hypoglycemia[NCT01468454]	Phase 2	130 participants (Actual)	Interventional	2009-01-31	Completed
The Use of Fluorodopa F 18 Positron Emission Tomography Combined With Computed Tomography in Congenital Hyperinsulinism and Insulinoma[NCT02021604]	Phase 1	250 participants (Anticipated)	Interventional	2013-10-09	Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Number of Participants with Adverse Events (NCT00674440)
Timeframe: 72 hours maximum or prior to pancreatic surgery

The Accuracy of FDOPA PET to Identify Focal Forms of Hyperinsulinism

Intervention	Participants (Count of Participants)
All Subjects Who Had PET	0

Comparison of PET scan results with outcome of surgery and histopathology results confirmed as focal or diffuse (NCT00674440)
Timeframe: up to 1 month post surgical intervention

Safety of 18F-DOPA PET/CT Scan - Number of Participants With Adverse Events

Intervention	Participants (Count of Participants)
	True Negatives (PET diffuse/surgery diffuse)	False negatives (PET diffuse/surgery focal):	False positives (PET focal/surgery diffuse):	True positives (PET focal/surgery focal):
Subjects Who Had PET and Surgery	40	6	3	46

"To further evaluate the safety of 18-labeled L-fluorodeoxyphenylalanine (18F-DOPA) PET/CT imaging in infants and children with congenital hyperinsulinism~- subjects are monitored clinically for any signs or symptoms of adverse events for 72 hours post PET. Adverse events are documented and followed to resolution" (NCT01468454)
Timeframe: evaluated with 72 hours or prior to pancreatic surgery (if any)

Accuracy of 18F-DOPA PET/CT Scans to Detect Focal Lesions in Children With Congenital Hyperinsulinism

Intervention	Participants (Count of Participants)
(18F-DOPA) PET/CT Imaging	0

To determine the sensitivity and specificity of 18F-DOPA PET/CT for the detection of a focal pancreatic lesion in infants and children with poorly controlled hyperinsulinemic hypoglycemia. (NCT01468454)
Timeframe: Surgery typically occured within a week post PET

Article	Year
Congenital hyperinsulinism - a review of the disorder and a discussion of the anesthesia management. Paediatric anaesthesia, 2007, Volume: 17, Issue:7 Topics: Anesthesia; Dihydroxyphenylalanine; Hepatic Veins; Humans; Hyperinsulinism; Infant; Infant, Newborn;	2007
Congenital hyperinsulinism - a review of the disorder and a discussion of the anesthesia management. Paediatric anaesthesia, 2007, Volume: 17, Issue:7 Topics: Anesthesia; Dihydroxyphenylalanine; Hepatic Veins; Humans; Hyperinsulinism; Infant; Infant, Newborn;	2007
Congenital hyperinsulinism - a review of the disorder and a discussion of the anesthesia management. Paediatric anaesthesia, 2007, Volume: 17, Issue:7 Topics: Anesthesia; Dihydroxyphenylalanine; Hepatic Veins; Humans; Hyperinsulinism; Infant; Infant, Newborn;	2007
Congenital hyperinsulinism - a review of the disorder and a discussion of the anesthesia management. Paediatric anaesthesia, 2007, Volume: 17, Issue:7 Topics: Anesthesia; Dihydroxyphenylalanine; Hepatic Veins; Humans; Hyperinsulinism; Infant; Infant, Newborn;	2007
6-L-18F-fluorodihydroxyphenylalanine PET in neuroendocrine tumors: basic aspects and emerging clinical applications. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2008, Volume: 49, Issue:4 Topics: Adenoma, Islet Cell; Dihydroxyphenylalanine; Humans; Hyperinsulinism; Neuroendocrine Tumors; Pancrea	2008

Article	Year
The effects of dietary weight loss on indices of norepinephrine turnover: modulatory influence of hyperinsulinemia. Obesity (Silver Spring, Md.), 2014, Volume: 22, Issue:3 Topics: Body Mass Index; Diet, Reducing; Dihydroxyphenylalanine; Down-Regulation; Energy Metabolism; Female;	2014
18F-FDOPA PET/CT imaging of insulinoma revisited. European journal of nuclear medicine and molecular imaging, 2015, Volume: 42, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Carbidopa; Dihydroxyphenylalanine; Female; Humans; Hyperinsulinism;	2015
Dynamic 18F-FDOPA PET Findings After Carbidopa Premedication in 2 Adult Patients With Insulinoma-Related Hyperinsulinemic Hypoglycemia. Clinical nuclear medicine, 2015, Volume: 40, Issue:8 Topics: Adult; Carbidopa; Dihydroxyphenylalanine; Female; Humans; Hyperinsulinism; Hypoglycemia; Insulinoma;	2015
[Sedation of infants with congenital hyperinsulinism during PET CAT scanning. A case collection]. Der Anaesthesist, 2008, Volume: 57, Issue:11 Topics: Blood Glucose; Conscious Sedation; Dihydroxyphenylalanine; Female; Glucose; Homeostasis; Humans; Hyp	2008
18F-FDOPA: a multiple-target molecule. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2009, Volume: 50, Issue:12 Topics: Adult; Biological Transport; Dihydroxyphenylalanine; Humans; Hyperinsulinism; Infant, Newborn; Neuro	2009
Limited value of 18F-F-DOPA PET to localize pancreatic insulin-secreting tumors in adults with hyperinsulinemic hypoglycemia. The Journal of clinical endocrinology and metabolism, 2010, Volume: 95, Issue:1 Topics: Adolescent; Adult; Aged; Child; Dihydroxyphenylalanine; Female; Humans; Hyperinsulinism; Hypoglycemi	2010
Functional imaging in hyperinsulinemic hypoglycemia after gastric bypass surgery for morbid obesity. The Journal of clinical endocrinology and metabolism, 2012, Volume: 97, Issue:6 Topics: Adult; Carbon Radioisotopes; Dihydroxyphenylalanine; Female; Fluorodeoxyglucose F18; Gastric Bypass;	2012
Congenital hyperinsulinism: pancreatic [18F]fluoro-L-dihydroxyphenylalanine (DOPA) positron emission tomography and immunohistochemistry study of DOPA decarboxylase and insulin secretion. The Journal of clinical endocrinology and metabolism, 2006, Volume: 91, Issue:3 Topics: Adolescent; Animals; Cell Line; Child; Child, Preschool; Dihydroxyphenylalanine; Dopa Decarboxylase;	2006
Accuracy of [18F]fluorodopa positron emission tomography for diagnosing and localizing focal congenital hyperinsulinism. The Journal of clinical endocrinology and metabolism, 2007, Volume: 92, Issue:12 Topics: Biopsy; Dihydroxyphenylalanine; Humans; Hyperinsulinism; Image Interpretation, Computer-Assisted; In	2007
Accuracy of [18F]fluorodopa positron emission tomography for diagnosing and localizing focal congenital hyperinsulinism. The Journal of clinical endocrinology and metabolism, 2007, Volume: 92, Issue:12 Topics: Biopsy; Dihydroxyphenylalanine; Humans; Hyperinsulinism; Image Interpretation, Computer-Assisted; In	2007
Accuracy of [18F]fluorodopa positron emission tomography for diagnosing and localizing focal congenital hyperinsulinism. The Journal of clinical endocrinology and metabolism, 2007, Volume: 92, Issue:12 Topics: Biopsy; Dihydroxyphenylalanine; Humans; Hyperinsulinism; Image Interpretation, Computer-Assisted; In	2007
Accuracy of [18F]fluorodopa positron emission tomography for diagnosing and localizing focal congenital hyperinsulinism. The Journal of clinical endocrinology and metabolism, 2007, Volume: 92, Issue:12 Topics: Biopsy; Dihydroxyphenylalanine; Humans; Hyperinsulinism; Image Interpretation, Computer-Assisted; In	2007
Accuracy of [18F]fluorodopa positron emission tomography for diagnosing and localizing focal congenital hyperinsulinism. The Journal of clinical endocrinology and metabolism, 2007, Volume: 92, Issue:12 Topics: Biopsy; Dihydroxyphenylalanine; Humans; Hyperinsulinism; Image Interpretation, Computer-Assisted; In	2007
Accuracy of [18F]fluorodopa positron emission tomography for diagnosing and localizing focal congenital hyperinsulinism. The Journal of clinical endocrinology and metabolism, 2007, Volume: 92, Issue:12 Topics: Biopsy; Dihydroxyphenylalanine; Humans; Hyperinsulinism; Image Interpretation, Computer-Assisted; In	2007
Accuracy of [18F]fluorodopa positron emission tomography for diagnosing and localizing focal congenital hyperinsulinism. The Journal of clinical endocrinology and metabolism, 2007, Volume: 92, Issue:12 Topics: Biopsy; Dihydroxyphenylalanine; Humans; Hyperinsulinism; Image Interpretation, Computer-Assisted; In	2007
Accuracy of [18F]fluorodopa positron emission tomography for diagnosing and localizing focal congenital hyperinsulinism. The Journal of clinical endocrinology and metabolism, 2007, Volume: 92, Issue:12 Topics: Biopsy; Dihydroxyphenylalanine; Humans; Hyperinsulinism; Image Interpretation, Computer-Assisted; In	2007
Accuracy of [18F]fluorodopa positron emission tomography for diagnosing and localizing focal congenital hyperinsulinism. The Journal of clinical endocrinology and metabolism, 2007, Volume: 92, Issue:12 Topics: Biopsy; Dihydroxyphenylalanine; Humans; Hyperinsulinism; Image Interpretation, Computer-Assisted; In	2007
Functional imaging of the pancreas: the role of [18F]fluoro-L-DOPA PET in the diagnosis of hyperinsulinism of infancy. Endocrine development, 2007, Volume: 12 Topics: Child, Preschool; Dihydroxyphenylalanine; Female; Fluorine Radioisotopes; Humans; Hyperinsulinism; I	2007
Congenital hyperinsulinism: [18F]DOPA PET/CT scan of a focal lesion in the head of the pancreas. Archives of disease in childhood. Fetal and neonatal edition, 2008, Volume: 93, Issue:2 Topics: Dihydroxyphenylalanine; Dopamine Agents; Humans; Hyperinsulinism; Image Interpretation, Computer-Ass	2008

dihydroxyphenylalanine and Hyperinsulinism